These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
359 related items for PubMed ID: 11181368
21. Cefpodoxime proxetil, its in vitro antibacterial activity, affinity to bacterial penicillin-binding proteins, and synergy of bactericidal activity with serum complement and mouse-cultured macrophages. Yokota T, Suzuki E, Arai K. Drugs Exp Clin Res; 1988; 14(8):495-500. PubMed ID: 3073932 [Abstract] [Full Text] [Related]
22. In vitro activity of ceftaroline (PPI-0903M, T-91825) against bacteria with defined resistance mechanisms and phenotypes. Mushtaq S, Warner M, Ge Y, Kaniga K, Livermore DM. J Antimicrob Chemother; 2007 Aug; 60(2):300-11. PubMed ID: 17548456 [Abstract] [Full Text] [Related]
23. Antimicrobial activity of SM-17466, a novel carbapenem antibiotic with potent activity against methicillin-resistant Staphylococcus aureus. Sumita Y, Nouda H, Kanazawa K, Fukasawa M. Antimicrob Agents Chemother; 1995 Apr; 39(4):910-6. PubMed ID: 7785994 [Abstract] [Full Text] [Related]
24. [In vitro antibacterial activity of a new parenteral penem, sulopenem]. Yoshida T, Tateda E, Hiramatsu K, Yokota T. Jpn J Antibiot; 1996 Apr; 49(4):324-37. PubMed ID: 8786624 [Abstract] [Full Text] [Related]
25. Ceftobiprole: a review of a broad-spectrum and anti-MRSA cephalosporin. Zhanel GG, Lam A, Schweizer F, Thomson K, Walkty A, Rubinstein E, Gin AS, Hoban DJ, Noreddin AM, Karlowsky JA. Am J Clin Dermatol; 2008 Apr; 9(4):245-54. PubMed ID: 18572975 [Abstract] [Full Text] [Related]
26. In vitro activity of nemonoxacin (TG-873870), a novel non-fluorinated quinolone, against clinical isolates of Staphylococcus aureus, enterococci and Streptococcus pneumoniae with various resistance phenotypes in Taiwan. Chen YH, Liu CY, Lu JJ, King CH, Hsueh PR. J Antimicrob Chemother; 2009 Dec; 64(6):1226-9. PubMed ID: 19833635 [Abstract] [Full Text] [Related]
28. Antibacterial activities in vitro and in vivo and pharmacokinetics of cefquinome (HR 111V), a new broad-spectrum cephalosporin. Limbert M, Isert D, Klesel N, Markus A, Seeger K, Seibert G, Schrinner E. Antimicrob Agents Chemother; 1991 Jan; 35(1):14-9. PubMed ID: 2014969 [Abstract] [Full Text] [Related]
29. In vitro and in vivo antibacterial activities of CS-807, a new oral cephalosporin. Utsui Y, Inoue M, Mitsuhashi S. Antimicrob Agents Chemother; 1987 Jul; 31(7):1085-92. PubMed ID: 3310868 [Abstract] [Full Text] [Related]
30. In vitro activities of RWJ-54428 (MC-02,479) against multiresistant gram-positive bacteria. Chamberland S, Blais J, Hoang M, Dinh C, Cotter D, Bond E, Gannon C, Park C, Malouin F, Dudley MN. Antimicrob Agents Chemother; 2001 May; 45(5):1422-30. PubMed ID: 11302805 [Abstract] [Full Text] [Related]
31. [Combination effect between panipenem and vancomycin on highly methicillin-resistant Staphylococcus aureus]. Fukuoka T, Domon H, Kakuta M, Ishii C, Hirasawa A, Utsui Y, Ohya S, Yasuda H. Jpn J Antibiot; 1997 Apr; 50(4):411-9. PubMed ID: 9192249 [Abstract] [Full Text] [Related]
32. In vitro antibacterial activity of KP-736, a new cephem antibiotic. Maejima T, Inoue M, Mitsuhashi S. Antimicrob Agents Chemother; 1991 Jan; 35(1):104-10. PubMed ID: 2014964 [Abstract] [Full Text] [Related]
33. In vitro activities of novel trans-3,5-disubstituted pyrrolidinylthio-1beta-methylcarbapenems with potent activities against methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa. Nagano R, Shibata K, Adachi Y, Imamura H, Hashizume T, Morishima H. Antimicrob Agents Chemother; 2000 Mar; 44(3):489-95. PubMed ID: 10681308 [Abstract] [Full Text] [Related]
34. Mode of action of the dual-action cephalosporin Ro 23-9424. Georgopapadakou NH, Bertasso A, Chan KK, Chapman JS, Cleeland R, Cummings LM, Dix BA, Keith DD. Antimicrob Agents Chemother; 1989 Jul; 33(7):1067-71. PubMed ID: 2675755 [Abstract] [Full Text] [Related]
35. The antimicrobial activity of cefpirome, a new cephalosporin. Wise R, Andrews JM, Cross C, Piddock LJ. J Antimicrob Chemother; 1985 Apr; 15(4):449-56. PubMed ID: 3874198 [Abstract] [Full Text] [Related]
36. Comparative in vitro activity of cefepime against nosocomial isolates. Sofianou D, Tsoulfa S, Kontodimou L, Polydorou F, Malaka E. J Chemother; 1997 Oct; 9(5):341-6. PubMed ID: 9373789 [Abstract] [Full Text] [Related]
37. In vitro and in vivo activities of DN-9550, a new broad-spectrum cephalosporin. Une T, Otani T, Sato M, Ikeuchi T, Osada Y, Ogawa H, Sato K, Mitsuhashi S. Antimicrob Agents Chemother; 1985 Apr; 27(4):473-8. PubMed ID: 3873898 [Abstract] [Full Text] [Related]
38. In vitro and in vivo antibacterial activities of OPC-20011, a novel parenteral broad-spectrum 2-oxaisocephem antibiotic. Matsumoto M, Tamaoka H, Ishikawa H, Kikuchi M. Antimicrob Agents Chemother; 1998 Nov; 42(11):2943-9. PubMed ID: 9797230 [Abstract] [Full Text] [Related]
39. TOC-39, a novel parenteral broad-spectrum cephalosporin with excellent activity against methicillin-resistant Staphylococcus aureus. Hanaki H, Akagi H, Masaru Y, Otani T, Hyodo A, Hiramatsu K. Antimicrob Agents Chemother; 1995 May; 39(5):1120-6. PubMed ID: 7625799 [Abstract] [Full Text] [Related]
40. TAK-599, a novel N-phosphono type prodrug of anti-MRSA cephalosporin T-91825: synthesis, physicochemical and pharmacological properties. Ishikawa T, Matsunaga N, Tawada H, Kuroda N, Nakayama Y, Ishibashi Y, Tomimoto M, Ikeda Y, Tagawa Y, Iizawa Y, Okonogi K, Hashiguchi S, Miyake A. Bioorg Med Chem; 2003 May 29; 11(11):2427-37. PubMed ID: 12735989 [Abstract] [Full Text] [Related] Page: [Previous] [Next] [New Search]